Biodesix, Inc.

BDSX Healthcare Diagnostics & Research

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.66 1.05 −4.25%
Market cap
$260.7M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
−7.46
Beneish M
−3.13
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
— — — 4 3 3 4 4 4
P/S ratio
— 0.13 0.13 2.14 2.66 2.26 2.98 2.78 0.58
Altman Z-Score
— — — (1.97) (4.84) (5.72) (5.77) (5.23) (7.46)
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
— (25.92) (22.77) (4.77) (14.92) (14.10) (16.14) (15.90) (19.59)
P/Operating CF
— (0.94) (0.94) (11.14) (14.20) (7.22) (11.90) (48.34) 66.00
Beneish M-Score
— — (2.17) (1.35) (3.80) (3.19) (3.50) (1.92) (3.13)
P/B ratio
— 0.00 0.00 2.37 7.34 4.19 31.91 9.48 0.00
Price to Tangible BV
— 0.00 0.00 7.58 0.00 0.00 0.00 0.00 0.00
EV/Sales
— 1.92 1.92 1.39 2.24 1.79 3.16 2.92 0.90
EV/EBITDA
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
— (2.80) (2.80) (2.96) (4.33) (1.52) (6.78) (4.28) (3.43)
EV/FCF
— (2.50) (2.50) (2.68) (3.97) (1.41) (3.38) (4.00) (3.37)
Quick Ratio
— 1.79 0.47 2.41 1.26 2.11 1.02 2.43 1.61
Current Ratio
— 2.22 0.56 2.68 1.51 2.34 1.19 2.76 1.87
Net Debt/EBITDA
— (1.04) (1.30) 2.42 0.65 0.46 (0.29) (0.39) (1.36)
Debt/Assets
0.00% 59.14% 79.88% 22.93% 13.16% 26.97% 35.60% 37.46% 54.24%
Debt/Equity
— (0.12) (0.16) 0.67 0.51 1.22 7.70 1.75 (19.25)
Asset Turnover
— 1.05 0.58 0.55 0.55 0.45 0.51 0.73 0.96
Operating CF/Net income
— 0.68 0.71 0.68 0.65 0.69 0.44 1.13 0.66
Capex/Depreciation
— 0.00 (0.44) (0.25) (0.43) (0.32) (2.16) (0.42) (0.06)
Interest Coverage
— (12.29) (8.89) (3.02) (9.08) (6.27) (4.34) (4.18) (3.61)
ROE
— 12.37% 14.52% 34.08% (141.75%) (324.53%) (414.09%) (337.30%) (383.09%)
ROA
— (133.99%) (73.08%) (37.75%) (43.78%) (77.45%) (54.32%) (43.73%) (38.18%)
ROIC
— 0.00% 0.00% (210.60%) 0.00% (1,229.75%) (190.38%) (69.42%) (67.00%)
Return on Tangible Assets
— (382.94%) 394.94% (54.81%) (229.18%) (180.08%) (152.77%) (81.01%) (88.39%)
Average Days of Receivables
— 33.80 78.67 122.61 24.48 48.38 57.10 44.03 37.27
Research and Development Expense of Revenue
— 40.07% 42.64% 23.75% 23.46% 34.29% 20.35% 13.40% 13.56%
Selling, General and Administrative Expense of Revenue
— 126.76% 124.78% 76.51% 92.68% 160.84% 137.28% 112.80% 98.92%
Intangible Assets out of Total Assets
0.00 0.71 0.67 0.23 0.35 0.27 0.23 0.22 0.22
Share Based Compensation of Revenue
— 0.00% 0.69% 8.14% 9.07% 15.60% 10.95% 9.31% 4.68%
Graham Net Nets
— (79.63) (79.63) 0.06 (0.09) (0.22) (0.38) (0.19) (1.12)
Graham Number
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.97
Earnings Yield
— (774.27%) (774.27%) (493.17%) (29.68%) (77.56%) (36.52%) (22.88%) (71.32%)
Free Cash Flow Yield
— (577.14%) (577.14%) (24.14%) (21.25%) (56.20%) (31.45%) (26.31%) (46.11%)
Revenue per Share
— 0.77 2,029.09 188.33 39.83 18.15 11.96 11.02 11.72
Operating CF per Share
— (0.67) (1,795.54) (88.33) (20.63) (21.36) (5.57) (7.52) (3.08)
Capex per Share
— 0.00 (117.02) (9.00) (1.86) (1.68) (5.62) (0.53) (0.05)
Free Cash Flow per Share
— (0.67) (1,912.56) (97.33) (22.49) (23.04) (11.19) (8.05) (3.14)
Cash per Share
— 0.23 436.86 256.83 23.91 20.47 6.40 4.06 2.51
Shareholders Equity per Share
— (7.46) (18,606.53) 170.18 14.42 9.79 1.12 3.23 (0.33)
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (7.46) (18,606.53) 170.18 14.42 9.79 1.12 3.23 (0.33)
Free Cash Flow
— (17.68) (23.14) (23.54) (30.77) (48.51) (45.93) (52.09) (23.67)
Working Capital
— 5.45 (9.90) 54.02 14.65 30.50 6.27 25.17 15.08
Capital Expenditures
— (0.62) (1.42) (2.18) (2.55) (3.53) (23.06) (3.44) (0.40)
Net Current Asset Value
— (43.21) (257.47) 6.24 (12.76) (18.97) (54.83) (36.88) (57.42)
EV/EBIT
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
— 0.00 0.06 0.05 0.05 0.09 0.47 0.05 0.00
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 1.25 1.51 2.74 1.41 1.87 0.38 0.29 0.28
Cash ROIC
— 10.47% 12.59% (17.96%) (49.27%) (54.66%) (69.45%) (62.34%) (37.01%)
Accounts Receivable Turnover
— 5.69 6.84 4.42 5.75 8.76 7.70 8.76 10.03
Accounts Payable Turnover
— 3.39 4.67 4.12 5.74 8.46 5.64 6.08 6.34
Inventory Turnover
— 5.87 8.10 11.00 10.01 6.58 0.00 0.00 0.00
Average Days of Payables
— 73.40 103.18 148.73 19.88 43.45 82.17 51.42 67.24
Days of Inventory on Hand
— 57.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
— 3.59 3.59 10.30 9.48 4.36 6.37 8.14 8.82
Average Payables
— 1.30 1.30 5.34 5.31 1.67 2.31 2.56 2.64
Average Inventory
— 0.75 0.75 2.00 3.05 2.15 — — —
Average Assets
— 19.53 42.05 83.05 98.58 84.50 96.00 98.17 92.36
Average Common Equity
— (211.58) (211.58) (91.99) 30.45 20.17 12.59 12.73 9.21

Fold the line items

Columns are period end dates